This study evaluating the PANKO-C57 model in combination with the investigations of others strongly alludes to PANDER being a potential therapeutic candidate for the treatment of hepatic insulin resistance and steatosis typically associated with T2D. Here, FAM3B is linked to type 2 diabetes mellitus.